Daclatasvir, as an NS5A inhibitor, is an important drug for treating hepatitis C. It is necessary to strictly follow the medication guidelines to ensure efficacy and safety. The following provides detailed explanations on indications, usage and dosage, and medication for special populations.

1 Indications

(1) Gene type 1 chronic hepatitis C: requires combination with other antiviral drugs such as sofosbuvir.

(2) Genotype 3 chronic hepatitis C: a recommended 12 week regimen in combination with sofosbuvir.

2 Usage and Dosage

(1) Standard dose: 60mg once daily, swallowed whole tablet.

(2) When combined with potent CYP3A4 inhibitors: reduce to 30mg once daily.

(3) When combined with moderate CYP3A4 inducer: increase to 90mg once daily.

3 Adjustments for Special Groups

(1) Liver dysfunction: Child Pugh B/C grade reduced to 30mg once daily.

(2) Renal insufficiency: No need to adjust dosage.

(3) Elderly patients: Individualized medication based on liver function status.

4 Medication precautions

(1) It must be swallowed whole and cannot be chewed or crushed.

(2) Avoid taking with proton pump inhibitors, with a 4-hour interval.

(3) Regular monitoring of liver function is required during treatment.

5 Adverse Reaction Management

(1) Common: fatigue, headache, nausea.

(2) Serious: Symptomatic bradycardia (when combined with amiodarone).

(3) If serious adverse reactions occur, seek medical attention immediately.